VirginiaDaleSteenMD
Rheumatology • Washington, DCProfessor, Medicine, Georgetown University School of Medicine
Dr. Steen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3800 Reservoir Rd Nw
Washington, DC 20007Phone+1 202-444-8233- Is this information wrong?
Education & Training
University of Pennsylvania Health SystemResidency, Internal Medicine, 1975 - 1977
University of Pittsburgh School of MedicineClass of 1975
Certifications & Licensure
DC State Medical License 1995 - 2024
VA State Medical License 1995 - 2000
PA State Medical License 1976 - 1998- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Rheumatology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2006-2014
- Top Doctors:Washington DC Area Castle Connolly, 2012
- Top Doctors:Washington-Baltimore Castle Connolly, 2012
- Join now to see all
Clinical Trials
- Placebo Controlled Trial of Bosentan in Scleroderma Patients Start of enrollment: 2006 Sep 01
- Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients Start of enrollment: 2005 Feb 01
- IVIG Treatment in Systemic Sclerosis Start of enrollment: 2013 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- Biomarker analysis from the phase 2b randomized placebo-controlled trial of riociguat in early diffuse cutaneous systemic sclerosis.Khanna, D., Kramer, F., Höfler, J., Ghadessi, M., Sandner, P., Allanore, Y., Denton, C., Kuwana, M., Matucci-Cerinic, M., Pope, J., Atsumi, T., Bečvář, R., Czirják, L....> ;Rheumatology. 2024 Mar 9
- Gerald P Rodnan.Virginia D Steen, Thomas A Medsger> ;Rheumatic Diseases Clinics of North America. 2024 Feb 1
- 1 citationsRiociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): open-label, long-term extension of a phase 2b, randomised, placebo-controlled trial.Oliver Distler, Yannick Allanore, Christopher P Denton, Masataka Kuwana, Marco Matucci-Cerinic, Janet E Pope, Tatsuya Atsumi, Radim Bečvář, László Czirják, Eric Hachul...> ;The Lancet. Rheumatology. 2023 Nov 1
- Join now to see all
Journal Articles
- The Scleroderma Patient-Centered Intervention Network Cohort: Baseline Clinical Features and Comparison with Other Large Scleroderma CohortsDaniel E Furst, Robert Spiera, Maureen D Mayes, Lorinda Chung, Suzanne Kafaja, Virginia Steen, Shervin Assassi, Monique Hinchcliff, Rheumatology
Other
- Pulmonary vascular disease in systemic sclerosis (scleroderma): TreatmentSteen V, Varga J
http://www.uptodate.com/contents/pulmonary-vascular-disease-in-systemic-sclerosis-scleroderma-treatm
UpToDate, Wolters Kluwer Health - 2012-04-23 - Pulmonary vascular disease in systemic sclerosis (scleroderma): Definition, classification, risk factors, screening, and prognosisSteen V, Varga J
http://www.uptodate.com/contents/pulmonary-vascular-disease-in-systemic-sclerosis-scleroderma-defini
UpToDate, Wolters Kluwer Health - 2013-02-09
Press Mentions
What Is Scleroderma? These Are the Signs You Could Have ItDecember 24th, 2019
Socioeconomic Status Affects Scleroderma Severity in African AmericansMarch 19th, 2019
Unmasking a DiseaseFebruary 18th, 2018
Hospital Affiliations
MedStar Georgetown University HospitalWashington, District of Columbia
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
